Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 37fludarabine phosphate 31Busulfan 25Antilymphocyte Serum 22Mycophenolic Acid 20Melphalan 19Cyclosporine 19Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Cord Blood Stem Cell Transplantation 16Whole-Body Irradiation 14Tacrolimus 14Radiotherapy 14Methylprednisolone 13fludarabine 11Methotrexate 8Epoetin Alfa 8Etoposide 7Cytarabine 7Thiotepa 6Alemtuzumab 6thymoglobulin 4Granulocyte Colony-Stimulating Factor 4Darbepoetin alfa 3Bone Marrow Transplantation 3Stem Cell Transplantation 2Sirolimus 2Rituximab 2Mesna 2Influenza Vaccines 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Glycopeptides × Classical hematology × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡